A Study of NTX-1472 in Social Anxiety Disorder
Public ClinicalTrials.gov record NCT07323784. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of NTX-1472, a V1a Receptor Antagonist, in Adults With Social Anxiety Disorder
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary goal of this Phase 2 clinical trial is to determine the effects of a novel V1a receptor antagonist (NTX-1472) in adults with Social Anxiety Disorder (SAD). The main questions this trial aims to answer are: * Is NTX-1472 safe and well tolerated in adults with SAD? * How effectively does NTX-1472 treat adults with SAD? Researchers will compare the effects of NTX-1472 with matching placebo (a look-alike capsule that contains no drug). Participants will: * Take NTX-1472 or matching placebo every day for 8 weeks * Visit the clinic 6 times over the course of 14 weeks for checkups and tests
Study identification
- NCT ID
- NCT07323784
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 100 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 8, 2025
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
- Last update posted
- Jul 8, 2026
2025 – 2027
United States locations
- U.S. sites
- 11
- U.S. states
- 7
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| SOAR Clinical Study Site | Encino | California | 91316 | Recruiting |
| SOAR Clinical Study Site | Los Angeles | California | 90025 | Recruiting |
| SOAR Clinical Study Site | Oceanside | California | 92056 | Recruiting |
| SOAR Clinical Study Site | San Jose | California | 95124 | Recruiting |
| SOAR Clinical Study Site | Jacksonville | Florida | 32256 | Recruiting |
| SOAR Clinical Study Site | Tampa | Florida | 33615 | Recruiting |
| SOAR Clinical Study Site | Boston | Massachusetts | 02131 | Recruiting |
| SOAR Clinical Study Site | Las Vegas | Nevada | 89119 | Active, not recruiting |
| SOAR Clinical Study Site | Brooklyn | New York | 11229 | Recruiting |
| SOAR Clinical Study Site | Memphis | Tennessee | 38119 | Recruiting |
| SOAR Clinical Study Site | Austin | Texas | 78737 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07323784, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 8, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07323784 live on ClinicalTrials.gov.